Overview
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)
Status:
Completed
Completed
Trial end date:
2013-10-01
2013-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to collect and assess information on safety and efficacy of fondaparinux in patients undergoing abdominal surgery in urology, obstetrics and gynecology departments who are at high risk of venous thromboembolism.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
GlaxoSmithKlineTreatments:
Fondaparinux
PENTA
Criteria
Inclusion Criteria:- Patients undergoing abdominal surgery in urology, obstetrics and gynecology
departments
Exclusion Criteria:
- Patients with a history of hypersensitivity to the ingredients of fondaparinux
- Patients with bleeding (bleeding in important organs, sucn as retroperitoneal bleed)
- Patients with acute bacterial endocarditis
- Patients with severe renal impairment